Date: 2013-02-20
Type of information: Interim results
phase: 1
Announcement: interim results
Company: ProtAffin (Austria)
Product: PA401
Action
mechanism: PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and other cells and its primary function is the attraction of neutrophils to sites of acute and chronic inflammation. PA401 acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is a hallmark of many respiratory diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
By binding to glycans with a higher affinity than wild-type IL-8, PA401 can prevent wild-type IL-8 from activating neutrophils and inhibit the events that would normally lead to infiltration of neutrophils and chronic lung inflammation.
PA401 is in clinical development for COPD, CF and related respiratory indications.
Disease: inflammatory lung disease
cystic fibrosis
Therapeutic area: Inflammatory diseases - Lung diseases - Rare diseases - Genetic diseases
Country: UK
Trial details:
Latest
news: * On February 20, 2013, ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for inflammation, respiratory disease and oncology, has announced that a collaboration with scientists at the Royal College of Surgeons in Ireland (RCSI), Dublin has generated promising pre-clinical results for the company’s lead anti-inflammatory product, PA401. The collaboration has shown that exposure of bronchoalveolar lavage fluid from patients with cystic fibrosis to increasing concentrations of PA401 significantly reduced the level of detectable IL-8 in that fluid. These results will be presented at the American Thoracic Society (ATS) International Conference in Philadelphia this May. Professor McElvaney, Director of the Respiratory Research Laboratory, RCSI, commented: "Clinical application of an IL-8 decoy such as PA401 could lessen the inflammatory burden in the cystic fibrosis lung”.
* On June 27, 2012, ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology, has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401. The company expects to complete the study by the end of 2012.
